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ant balloon and should be incorporated into the stent deployment protocol.
2) Luminal improvement after high pressure inflation is not recognized by
conventional angiography.
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Antonio Colombo. Shigeru Nakamura, Patrick Hall, Luigi Maieilo, Massimo Ferraro,
Giovanni Martini, Simonetta Blengino, Leo Finci. Columbus Hospital, Milan, Italy
The Gianturco Roubin (GR) coronary stent has been implanted in 91 lesions
in 78 patients. The indications for stent implantation were 41 elective (45%).
17 chronic total occlusion (19%). 10 acute occlusion (11%). 9 threatened
closure (10%). 8 restenosis (9%) and 6 suboptimal PTCA (7%). Vessel distri-
bution was 50 LAD (55%), 21 RCA (23%). 18 LCX (20%) and 2 SVG 12%1. Suc-
cessful stent implantation was achieved in 72 patients (92%). Average GR
stent per lesion was 1.4 ± 0.5 (range 1 to 3). More than 1 stent was used in
44 patients (61 %). Lesion length was 16.3 ± 9.1 mm. Final balloon/vessel ra-
tion was 1.17 ± 0.15. Maximum inflation pressure was 16 ± 3 atmospheres.
An additional stent inside the GR stent was required in 5 lesions (6%) to
reinforce plaque prolapse. A Palmaz-Schatz used in 4 lesions and a GR in
1 lesion. After stent implantation with intravascular ultrasound guidance, 60
patients (83%) with 71 lesions (82%) were treated only with antiplatelet ther-
apy without anticoagulation. Procedure related major complication included
3 emergency CABG 14%) and one death (1 %). To date, 35 of an eligible 54 le-
sions (64%). received 4-6 months angiographic follow up (F/U). Quantitative
angiographic measurements are summarized in the table below:
Rajbabu Pakala, James 1. Willerson, Claude R. Benedict. University of Texas Medical
School, Houston, Texas
Background: Thromboxane A2 (TxA2) and serotonin (5HT) released from ag-
gregating platelets are known mitogens for vascular smooth muscle cells
(SMC). Recently we reported that TxA2 and 5HT act synergistically in induc-
ing proliferation of SMC and may contribute to the development of resteno-
sis following vascular injury.
Purpose: In this study, we examined whether ridogrel (a TxA2 synthase
inhibitor/receptor antagonist) can inhibit the TxA2 induced SMC proliferation
both in the presence and absence of 5HT.
Methods: Canine aortic primary SMC were preincubated with either 30
Ilg/ml of Ridogrel in phosphate buffered saline (PBS) or equal volume of
PBS, as control, for 2 hrs in serum free medium. Increasing concentrations
of U46619 (a TxA2 mimetic) with or without 5HT were then added and 3H_
thymidine incorporated into DNA of the SMC was measured.
Resu/ts:
50o
Rido9rel 30 Ilg/ml
5HT ConcentrationlllMI
50
Mitogenic Effect of Thromboxane A2 and Its
Synergistic Interaction with Serotonin on Smooth
Muscle Cell Proliferation is Reversed by Ridogrel
Control (PBS)
5HT Concentration(IlM)
o
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% stenosis
72 ± 20
6 ± 17
38 ± 32
Lesion (mml
0.85 ± 0.67
2.79 ± 0.52
1.78 ± 0.96
Reference (mm)
2.97 ± 0.49
300 ± 0.47
2.96 ± 0.57
AG results
Baseline
Post stent
FlU
Values are % of control: Control ~ 100% ~ 9023 ± 621 cpml106 cells. n ~ 3, *p < 0.001
compared to corresponding PBS treated controls
* p ~ < 0.05 pre vs post. post vs 28 days. 1 p = 0.0001 heparin vs hirulog at 28 days
By histomorphometric analysis, percent cross-sectional area narrowing by
plaque (CSAN-P)was 56 ± 24% and 42 ± 21 % in heparin-and hirulog-treated
vessels, respectively (p = 0.04). In addition, 14 of 21 heparin controls but only
7 of 23 hirulog vessels had >50% CSAN-P (p = 0.03, heparin vs hirulog).
212 ± 13
249 ± 6*
279 ± 17*
274 ± 21*
306 ± 3
294 ± 27*
283 ± 24*
285 ± 28*
68 ± 4
84 ± 8
74 ± 11*
76 ± 2*
28 Days
1.0 ± O.4*t
1.5 ± 0.21
222 ± 5
1131 ± 97
1369 ± 146
1569± 103
Post-SA
1.5 ± 0.2*
1.6 ± 01*
236 ± 37
394 ± 20
541 ± 69
795 ± 22
100
100 ± 1
173 ± 29
282 ± 8
Pre-BA
1.1 ± 0.2
1.2 ± 0.1
TxA2 0 nM
TxA2 7.5 nM
TxA2 75 nmM
TxA2 750 nM
Effectiveness of Recombinant Hirulog" in
Reducing Restenosis After Balloon Angioplasty in
the Atherosclerotic Rabbit
Leonard M. Thome, S. David Gertz, Lawrence W. Gimple, Kyle W. McCoy, Eric
R. Powers, John M. Maraganore, Ian J, Sarembock. University of Virginia,
Charlottesville, VA
Thrombin may playa central role in restenosis after balloon angioplasty (BAI,
and angiographic and pathologic restenosis have been shown to be reduced
in the rabbit model using recombinant desulfatohirudin, a selective thrombin
inhibitor. We hypothesized that an intravenous infusion of hirulog, a 20 amino
acid potent and selective thrombin inhibitor, given at the time of angioplasty
would reduce restenosis in the atherosclerotic rabbit model. Focal femoral
atherosclerosis was induced in 27 rabbits by air desiccation endothelial in-
jury followed by a 2% cholesterol diet for 1 month. At BA (2.5 mm balloon
with three 60-second, 10 atm inflations 60 seconds apart). rabbits received
either heparin (150 units/kg bolus, n = 14) or hirulog (5 mglkg bolus followed
by 5 mglkg/hr x 2 hours, n = 13). Angiograms performed before and after
BA and at 28 days were analyzed quantitatively by two blinded observers.
Rabbits were sacrificed 28 days after BA, and quantitative histomorphome-
tric analysis was performed on all vessels. The angiographic mean luminal
diameters (LDI in mm were:
The data show that unlike the PBS treated controls, ridogrel reversed both
the mitogenic effect of TxA2 on SMC as well as its synergistic interaction
with 5HT in inducing cellular proliferation.
Conclusion: The data indicate the specificity of the interaction of TxA2 with
5HT in inducing SMC proliferation. This suggests a potential role forthe com-
bined use of TxAZ synthase inhibitor/receptor antagonist and 5HT receptor
antagonist for inhibiting SMC proliferation at sites of vascular injury.
Heparin
Hirulog
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Ultrasound Guided Coronary Stent Placement
without Prolonged Systemic Anticoagulation
Robert J. Russo, Richard A. Schatz, Mitchel A. Sklar, Allen D. Johnson, Jonathan
M. Tobis, Paul S. Teirstein. Scripps Clinic and Research Foundation, La Jolla, CA
Over a five-month period, 83 consecutive patients undergoing elective
Palmaz-Schatz stent placement in a target vessel of greater than 3.2 mm
in diameter were evaluated for early hospital discharge without anticoagula-
tion. Thirty-nine patients failed to meet angiographic or clinical criteria due to
the presence of dissection (11 patients). TIMI flow <3 (11), filling defects (7).
a persistent angiographic stenosis (6) or stent placement in sole-remaining
circulation (4). The average final balloon size after stent placement was 4.5
mm (range 3.5 to 6.0 mm) and minimal luminal diameter within the stent was
3.75 mm (range 3.0 to 4.0 mm). In the remaining 44 patients, intravascular
ultrasound (IVUS) was performed after a definitive angiographic result had
been obtained to determine if previously established criteria (stenosis, ap-
position and symmetry) for discharge without anticoagulation had been ful-
filled. Twenty-one patients (77%) met criteria after the initiallVUS evaluation
and six (23%1 after reinflation with larger balloons. Seventeen patients failed
to meet IVUS criteria: 14 due to a persistent area stenosis of > 15%, one
who lacked apposition in an aneurysmal segment, one with an angiographi-
cally occult dissection and one who achieved <60% of the reference vessel
cross-sectional area. Of the 27 stents meeting IVUS criteria, mean eccentric-
itywas 0.86 (range 0.75 to 0.98), residual stenosis was -0.8% (range -31 to
15%) and minimal stent diameter 3.82 mm (range 3.0 to 5.0 mm). One patient
met angiographic and IVUS criteria but received prolonged anticoagulation
due to preference of the referring physician. Mean elapsed time from stent
placement to femoral sheath removal was 8.2 hours (range 1 to 29 hours).
Patients were discharged from the hospital within 48 hours of stent place-
ment, all receiving aspirin 325 mg per day and ticlopidine 250 mg twice a day.
At 30 days of clinical follow-up, no patients experienced stent thrombosis.
Conclusion: In this highly selective group of patients undergoing elective
stent placement in larger diameter vessels who fulfilled strict clinical, angio-
graphic and IVUS criteria, early discharge on aspirin and ticlopidine without
systemic anticoagulation was not associated with stent thrombosis.
The majority of patients were treated with only antiplatelet therapy after
successful stent implantation. There was no stent thrombosis or vascular
complications, The GR coronary stent restenosis rate by ~50% diameter
stenosis was 32% (n = 11 lesions).
Conclusions. (1) When optimal GR stent expansion was achieved, there
was no stent thrombosis despite the absence of anticoagulation in the ma-
jority of patients. (2) In the cases with plaque prolapse, overlapping stents
were an effective method to reinforce lumen support. (31 The restenosis rate
after Gianturco Roubin stent implantation is favorable when considering the
high incidence of bailout procedures, long lesion length and small reference
vessel diameter of this cohort.
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NEOINTIMA
Pulse Dosing of Recombinant Basic Fibroblast
Growth Factor Linked to Saporin Mitotoxin
Suppresses Neointimal Proliferation After
Balloon Injury
• Vehicle
11III15 Ilglkg
°
0.1
n
i
<,0.05
~
The mitotoxin bFGF-SAP combines the targeting specificity of basic fibrob-
last growth factor (bFGF) with the cytotoxicity of the ribosome inactivating
protein saporin (SAP) to exert a cytotoxic effect on proliferating smooth mus-
cle cells after arterial injury. Sprague-Dawley rats undervvent carotid artery
balloon injury and received an intravenous bolus of vehicle (n = 12). 5 (n =
10), 15 In = 11), or 20 (n = 10) JLg/kg bFGF-SAP at 0, 3, 6, and 9 days after
injury. Rats were euthanized at 14 days, and carotid arteries were analyzed
by computerized morphometry.
Results:
Andrew Farb 1. Sue J. Lee 1, Margie Mohler 2. Jennifer Cook 2, John McDonald 2,
Renu V"man,1. 1Armed Forces Institute of Pathology, Washington, DC; 2 PRiZM
Pharmaceuticals, San Diego, CA
The threshold pulse dose for reduced neointimal proliferation by bFGF-
SAP was 15 /Lgfkg with no further reduction in proliferation with 20 JL9/kg.
Reduced neointimal proliferation did not reach statistical significance with
the 5 /Lgfkg dose. When given as a continuous intravenous infusion (n =
8 ratsl at 15 /Lg/kg/day for 14-days after arterial injury (cumulative dose of
210 JLg/kgl, bFGF-SAP did not inhibit neointima formation. Arterial medial
thickness and area within the internal elastic lamina were similar in all groups.
Conclusion: Pulse dosing, but not a continuous infusion, of bFGF-SAP re-
sulted in a 46% reduction in neointimal proliferation after arterial injury. The
effect of bFGF-SAP appears to be selective for the neointima as there was
no associated medial thinning or arterial wall dilatation. Further studies op-
timizing the administration of bFGF-SAP and evaluation of its mechanism of
action will be important in utilizing this mitotoxin in the prevention of resteno-
sis.
Conclusion: Periadventitially applied polymeric fl-cyciodextrin sulfate pro-
duces sustained inhibition of intimal thickening following vascular injury, pos-
sibly by modulating cellular processes mediated by heparin binding growth
factors.
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Smooth muscle cell proliferation is critical to the pathogenesis of restenosis.
Oxygen-derived radicals are known cell mitogens. We tested whether ebse-
len, a selenium-containing heterocyclic compound with antioxidant activity
could reduce intimal thickening and increase luminal size after balloon injury
(81) in the coronary artery model. Nineteen normolipemic pigs were given
(811 of the LAD and LCX coronary arteries. At random 9 pigs were pretreated
with ebselen (2.4 g twice per day) for 3 days before 81 and continued un-
til sacrifice (2 weeks after BI). Coronary atrery sections were evaluated by
computer morphometry. The maximal intimal thickness (MIT), intimal area
(IA) luminal perimeter (LP). vessel perimeter (VP), and fracture length (FL)
Selenium-Containing Antioxidant (Ebselen)
Improves the Response to Balloon Injury in the
Pig Coronary Model: Effects on Vascular
Remodeling
Ron Waksman, Keith A. Robinson, Joel Schneider, Gustavo Cipolla,
Hiroyuki Masayasu. Spencer B. King III. Emory University School of Medicine,
Adanta. Georgia; Daiichi Pharmaceutical Co., Tokyo, Japan
Low Molecular Weight Heparin and Hirudin
Reduce Neointimal Proliferation After Coronary
Angioplasty
Sustained Inhibition of Intimal Thickening:
Beneficial In Vitro and In Vivo Effects of
Polymeric p·Cyclodextrin Sulfate
PEG-H 3 days PEG-H 14days CLl14 days CON
1 mg/kg bolus 1 mg/kg bolus 150 Uikg bolus 100 U/kg
5 mg/kg 1xlday 5 mglkg 75 Ulkg heparin-
In ~ 11) 1xlday 2x/day bolus
(n ~ 9) In ~ 8) In ~ 7)
Injury score 1.7 ± 0.4 2.2 ± 0.4 2.1±0.4 1.8 ± 0.3
Mean neointimal
thickness (mm) 0.33 ± 015 # 037±016# 039 ± 015 # 0.68 ± 0.18
Vessel wall area
(% vessel area) 47.0 ± 7.6 # 54.4 ± 9.4 # 51.5±21.4# 74 ± 113
#p < 0.02 vs CON
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In conclusion, a 2-hour infusion of hirulog at the time of angioplasty re-
duced angiographic restenosis as well as cross-sectional area narrowing by
plaque in this atherosclerotic rabbit model.
Conclusion: 80th CLI and PEG-H reduce neointimal proliferation after coro-
nary angioplasty, compared to standard clinical anticoagulation with a hep-
arin bolus.
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Arnd B. Buchwald, Christina Unterberg, Stefan Hammerschmidt, Heinrich Kreuzer.
Dept. of Cardiology, University Clinic, Gottingen. Germany
Proliferation of medial smooth muscle cells (SMC) plays a major role in
restenosis after coronary angioplasty and can be inhibited by heparin.
Platelets stimulate SMC proliferation and their aggregation post angioplasty
can be reduced by the direct thrombin inhibitor hirudin. In a porcine coro-
nary stent angioplasty model we studied the effect of 3 and 14 days treat-
ment with a novel polyethylenglycol - conjugated hirudin (PEG-H) versus
chronic low molecular weight heparin ciivarine (CLI) versus acute unfraction-
ated heparin as a control (CON). 4 weeks post a gioplasty, hearts were periu-
sion fixed and 6 slices per angioplasty segment were analysed for neointimal
thickness and vessel wall area (% of total vessel crossectional area). Vessel
injury in each slice was assessed using a semiquantitative score (0: lamina
elastica interna intact, to 3: penetration through media). PEG-H prolonged
partial thromboplastin time to 2-2.5 x control throughout treatment period.
Results:
William B. Bachinsky, Michael A. Golden, S. Steven Okada. John Tomaszewski,
Paul B. Weisz, Elliot S. Barnathan. University ofPennsylvania. Phliadelphia, PA
Intimal thickening after vascular injury is thought to be modulated in part by
heparin binding growth factors. We hypothesized that placement of a thera-
peutic polymer in the periadventitial space capable of tightly binding growth
factors might alter the vascular response to injury. We first tested the effects
of polymeric fl-cyclodextrin sulfate (P-CDS) on smooth muscle cell (SMC)
proliferation using a quantitative protein accumulation assay. Incubation of
rat aortic SMC (2500 cells/microwell in 10% FCS, n = 96) with P-CDS was
associated with a dose dependent inhibition of proliferation. with maximum
inhibition "'50% vs. control at 1 mg/ml (p < 0.05). The proliferation assays
were repeated using media containing only recombinant basic FGF (bFGF,
5 ng/ml) which had been exposed to P-CDS (1 mg/ml) for varying periods
of time (1 min to 3 days). We demonstrated a time dependent reduction of
the bFGF mitogenic activity, with complete removal of all activity within 60
minutes. Using radiolabeled bFGF (0.25 JLg/ml), we observed rapid associ-
ation (0.23 min-1) and dissociation (7.3 x 10-5 min-1) rates, suggesting a
high affinity interaction. We then tested the effects of P-CDS on SMC mi-
gration (using a linear under-agarose assay) and demonstrated treatment of
rat aortic SMC with P-CDS (1 mg/ml) in the agar resulted in "'50% reduction
in SMC migration vs. control at 72 hours (p < 0.05). Finally, the effects of
P-CDS in vivo were studied in the rat carotid balloon injury model. SD rats
("'350 g) were randomized to periadventitial P-CDS (10 mg) or no treatment,
additional rats received treatment with unsulfated fl-cyclodextrin polymer(P-
CD). Morphometric analyses at 4 (n = 20), 14 (n = 59), and 88 days (n = 14)
demonstrated >40% reduction of intimal area and intima/media area ratios
only in the P-CDS rats. No inhibition was seen with P-CD treated rats. De-
creased bromodeoxyuridine labeled SMC (79 ± 11 vs 144 ± 23, p = 0.Q1)
were noted in the intima of P-CDS rats at 14 days. At all time points, there
were reduced total SMC counts and no reduction in % proliferation in the
intima of P-CDS rats, suggesting greater effects on SMC migration than pro-
liferation in vivo. Endothelial cell regrowth (by Evans blue staining) was in-
creased in the P-CDS rats at 14 (4.4 vs 2.2 mm, p = 0.09) and 88 days (13.0
vs 9.2 mm, p < 0.01).
